Group 1 - The core viewpoint of the article highlights the recent stock performance of Innovent Biologics, which saw a 2.1% decline, trading at 97.85 CNY per share with a transaction volume of 3.855 billion CNY as of July 30 [1] - Innovent Biologics focuses on the research, development, production, and sales of innovative drugs targeting major diseases such as tumors, autoimmune diseases, metabolic disorders, and ophthalmology, having successfully launched 10 products [1] - As of October 2023, the company has 4 products under review, 4 new drug molecules in Phase III or pivotal clinical studies, and 18 new drug candidates in clinical research [1] Group 2 - For the fiscal year ending 2024, Innovent Biologics reported total revenue of 9.422 billion CNY and a net loss of 94.631 million CNY [2] - The company's patient assistance program has benefited over 170,000 patients, with a total value of drug donations reaching 3.4 billion CNY [1]
信达生物(01801)下跌2.1%,报97.85元/股